IXICO to provide specialist imaging services in Phase II Huntington’s disease clinical trial

590

IXICO, the digital technologies company serving neuroscience, today announces that it has signed a new contract with a North American based biopharmaceutical company. The contract value is £1.2m over a three year term.

IXICO will provide its technology enabled imaging services in a Phase II clinical trial of a novel therapeutic to treat people with Huntington’s disease. As part of the study, IXICO will use its TrialTracker™ digital platform and scientific services to standardise the acquisition and collection of both MRI and PET scans acquired at specialist imaging centres across North America. This data will be analysed using IXICO’s proprietary image analysis workflows and algorithms to evaluate patient eligibility, monitor patient safety and quantify drug effects.

DOWNLOAD FULL PRESS RELEASE

Source: IXICO PLC.



Print Friendly, PDF & Email